Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002844
Status:
COMPLETED
Last Update Posted:
2018-10-25
First Post:
1999-11-01
Brief Title:
Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Bone Marrow Transplantation for Chronic Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells
PURPOSE Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with chronic lymphocytic leukemia
PURPOSE Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with chronic lymphocytic leukemia
Detailed Description:
OBJECTIVES Examine the potential role for high dose cyclophosphamide total body irradiation and bone marrow transplantation for patients with chronic lymphocytic leukemia who are at high risk for disease progression
OUTLINE Patients receive daily intravenous infusions of cyclophosphamide for two days followed by total body irradiation in four daily exposures After completion of the total body irradiation allogeneic or autologous bone marrow is infused intravenously
PROJECTED ACCRUAL 50 patients are expected to be accrued
OUTLINE Patients receive daily intravenous infusions of cyclophosphamide for two days followed by total body irradiation in four daily exposures After completion of the total body irradiation allogeneic or autologous bone marrow is infused intravenously
PROJECTED ACCRUAL 50 patients are expected to be accrued
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000065081 | REGISTRY | NCI PDQ | httpsreporternihgovquickSearchP30CA016672 |
| P30CA016672 | NIH | None | None |
| MDA-DM-90106 | OTHER | None | None |
| NCI-G96-1034 | None | None | None |